Hepatic insulin gene therapy prevents diabetic enteropathy in STZ-treated CD-1 mice

• Published in: Molecular therapy. Methods & clinical development Vol. 2; p. 15028
• Main Authors: You, Shuo, Anitha, Mallappa, deSouza, Sean Md, Jia, Dingwu, Lu, Xianghua, Kozlowski, Miroslaw, Olson, Darin E, Srinivasan, Shanthi, Thulé, Peter M
• Format: Journal Article
• Language: English
• Published: United States Elsevier Limited 01-01-2015; Nature Publishing Group; Elsevier
• ISSN: 2329-0501; 2329-0501
• DOI: 10.1038/mtm.2015.28

Depending on the population examined, from 6 to 83% of people with diabetes mellitus exhibit symptoms of altered gut motility, manifesting as dysphagia, reflux, early satiety, nausea, abdominal pain, diarrhea, or constipation. Hyperglycemia-induced cell loss within the enteric nervous system has been demonstrated in both diabetic rodents and patients with diabetes. Glycemic control is recommended to prevent diabetic gastroenteropathy but is often difficult to achieve with current treatment modalities. We asked if hepatic insulin gene therapy (HIGT) could inhibit the development of diabetic gastroenteropathy in mice. Bowel length, bowel transit, colonic muscle relaxation, and the numbers of both stimulatory and inhibitory neurons in the colonic myenteric plexus were compared in groups of diabetic mice (DM), control nondiabetic mice (Con), and diabetic mice treated with HIGT (HIGT). Delivery of a metabolically responsive insulin transgene to the liver of STZ-diabetic mice with an adeno-associated virus, sero-type 8 (AAV8) produced near-normal blood sugars for over 1 month and prevented anatomic, functional, and neurohistologic changes observed in diabetic mice. We conclude that in addition to normalizing oxidative metabolism in diabetic rodents, HIGT is sufficient to prevent the development of diabetic gastroenteropathy.